New Research Sheds Light on Side Effects of Cancer Immunotherapy

A multinational study published in the journal Immunity and co-led by researchers at the Garvan Institute of Medical Research disclose why some cancer patients undergoing checkpoint inhibitor therapy are more susceptible to common infections. The findings offer critical insights into immune system responses and point to potential strategies for mitigating these side effects.

Checkpoint Inhibitors: A Double-Edged Sword